Prosecution Insights
Last updated: October 25, 2026

Biocardia Inc.

Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering

2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready

Analysis

Biocardia Inc. has 2 pending office actions in Medical Devices & Mechanical Engineering. The matters are assigned to 2 distinct examiners and 2 distinct art units. AHMED, TASNIM M is the busiest examiner, with 1 pending matter. The data shows distributed examination across separate assignments.

Counsel should preserve consistent descriptions of the medical-device technology while treating each examiner’s objections independently. Structural limitations, deployment or operating steps, and functional results should be separated clearly in the claims and response. The different art units may affect the relevant prior-art framing, making matter-specific analysis important. A coordinated portfolio review can reduce inconsistent terminology, but the examiner distribution means that amendment and interview decisions should follow the record for each pending matter.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

2
Total Pending OAs
2
Non-Final OAs
0
Final Rejections
0
Advisory / Quayle

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

1
Hard (50%)
0
Medium (0%)
1
Easy (50%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§101 + other1 (50%)
Double-patenting only1 (50%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

1
Life Sciences
50% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
1
Mechanical / Eng
50% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

20 h
Manual time on pending OAs
4 h
Time saved (low, 20%)
7 h
Time saved (mid, 35%)
0.2 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
AHMED, TASNIM M 1 81.4% +4.9%
FIEBIG, RUSSELL G 1 62.6% +25.0%

Quick Wins (1)

Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18774349 Method of Accessing A Vascular Site With A Multi-Directional Steerable Catheter AHMED, TASNIM M —

Hard Cases (1)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18343698 FETAL STROMAL CELL DERIVED EXOSOMES FOR TISSUE REPAIR FIEBIG, RUSSELL G —

Interview Candidates (1)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18343698 FETAL STROMAL CELL DERIVED EXOSOMES FOR TISSUE REPAIR FIEBIG, RUSSELL G —

Top Art Units

Art UnitApps
3783 1
1655 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18774349 Method of Accessing A Vascular Site With A Multi-Directional Steerable Catheter AHMED, TASNIM M 3783 DP Non-Final OA — Pending Jul 16, 2024
18343698 FETAL STROMAL CELL DERIVED EXOSOMES FOR TISSUE REPAIR FIEBIG, RUSSELL G 1655 §101§102§112 Non-Final OA — Pending Jun 28, 2023

Managing Biocardia Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Frequently Asked Questions

How many pending USPTO office actions does Biocardia Inc. have?

Biocardia Inc. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.

Which USPTO examiner handles the most Biocardia Inc. applications?

Tasnim M Ahmed has the most, with 1 of Biocardia Inc.'s pending office actions.

What technology area are Biocardia Inc.'s patent applications in?

Mostly Medical Devices & Mechanical Engineering (USPTO Tech Center 3700), based on where its pending office actions are examined.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month